Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
SAB Biotherapeutics (SABS)
NASDAQ:SABS
RESEARCH TOOLSreports
SAB Biotherapeutics (SABS) Stock Price & Analysis
55 Followers
SABS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.65 - $14.50
Previous Close$5.52
Volume98.41K
Average Volume (3M)19.18K
Market Cap
$55.35M
Enterprise Value$57.58M
Total Cash (Recent Filing)$2.43M
Total Debt (Recent Filing)$4.65M
Price to Earnings (P/E)-1.0
Beta1.49
Next Earnings
Mar 28, 2024EPS Estimate
-$0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.36
Shares Outstanding9,225,664
10 Day Avg. Volume31,053
30 Day Avg. Volume19,183
Standard Deviation0.32
R-Squared0.03
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)3.63
Price to Sales (P/S)23.57
Price to Cash Flow (P/CF)-2.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue29.77
Enterprise Value/Gross Profit2.41
Enterprise Value/Ebitda-3.01
Forecast
1Y Price Target
$10.00Price Target Upside81.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
SAB Biotherapeutics News
PremiumPress Releases
SAB Biotherapeutics Provides SAB-142 Trial Update
PremiumCompany Announcements
SAB Biotherapeutics Advances SAB-142 in Phase One Trials
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SABS FAQ
What was SAB Biotherapeutics’s price range in the past 12 months?
SAB Biotherapeutics lowest stock price was $3.65 and its highest was $14.50 in the past 12 months.
What is SAB Biotherapeutics’s market cap?
Currently, no data Available
When is SAB Biotherapeutics’s upcoming earnings report date?
SAB Biotherapeutics’s upcoming earnings report date is Mar 28, 2024 which is 19 days ago.
How were SAB Biotherapeutics’s earnings last quarter?
SAB Biotherapeutics released its earnings results on Nov 14, 2023. The company reported -$1 earnings per share for the quarter, beating the consensus estimate of -$1.167 by $0.167.
Is SAB Biotherapeutics overvalued?
According to Wall Street analysts SAB Biotherapeutics’s price is currently Undervalued.
Does SAB Biotherapeutics pay dividends?
SAB Biotherapeutics does not currently pay dividends.
What is SAB Biotherapeutics’s EPS estimate?
SAB Biotherapeutics’s EPS estimate is -$0.62.
How many shares outstanding does SAB Biotherapeutics have?
SAB Biotherapeutics has 9,225,664 shares outstanding.
What happened to SAB Biotherapeutics’s price movement after its last earnings report?
SAB Biotherapeutics reported an EPS of -$1 in its last earnings report, beating expectations of -$1.167. Following the earnings report the stock price went down -2.151%.
Which hedge fund is a major shareholder of SAB Biotherapeutics?
Among the largest hedge funds holding SAB Biotherapeutics’s share is RA Capital Management. It holds SAB Biotherapeutics’s shares valued at 16M.
---
SAB Biotherapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (81.16% Upside)
$10.00 (81.16% Upside)
Hedge Fund Trend
Increased
By 2.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
8.23%
12-Months-Change
Fundamentals
Return on Equity
-118.62%
Trailing 12-Months
Asset Growth
-46.03%
Trailing 12-Months
Company Description
SAB Biotherapeutics
Blue Calypso Inc is engaged in the development, sales, delivery and licensing of technology and intellectual property focused on mobile shopper engagement, digital word of mouth and location-based marketing and advertising. Its solutions include mobile engagement, POP and merchandise tracking, mobile plant tag engagement. The company derives its revenues from the cloud-based consumption of its technology platform, consulting fees and licensing of its technologies.
---
SABS Stock 12 Months Forecast
Average Price Target
$10.00
▲(81.16% Upside)
Technical Analysis
Best Analysts Covering SABS
1 Year
1 Year Success Rate
0/11 ratings generated profit
1 Year Average Return
-42.15%
reiterated a buy rating 5 months ago
Copying Keay Nakae's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -42.15% per trade.
---